VIDEO: Castration-resistant prostate cancer quality of life studies favor lutetium arms
Click Here to Manage Email Alerts
In this video, Alexander Chehrazi-Raffle, MD, discusses the results of three studies into quality-of-life outcomes in metastatic castration-resistant prostate cancer, presented at ASCO Annual Meeting.
Chehrazi-Raffle, a medical oncologist at the City of Hope Duarte Cancer Center, examined the PSMAfore, EMBARK and PRESTO studies, all three of which favored the lutetium arms of their respective cohorts.
“[The studies] showed us that there was a benefit to lutetium in the early [metastatic castration-resistant prostate cancer] setting, compared to the [androgen receptor pathway inhibitors] switch control arm, really arguing that that quality of life is being improved for patients in this context,” Chehrazi-Raffle said.
Collapse
Click Here to Manage Email Alerts